DBV Technologies :Data at AAAAI 2017 Show Lasting Response and Favorable Safety Profile of Investigational Agent, Viaskin Peanut, Throughout Three Years of Treatment of Peanut Allergic Children
(Thomson Reuters ONE) -
Press Release
Montrouge, France, March 5, 2017
Data at AAAAI 2017 Show Lasting Response and Favorable Safety Profile of
Investigational Agent, Viaskin Peanut, Throughout Three Years of Treatment of
Peanut Allergic Children
During a Late Breaking Oral Abstract Session, Dr. Shreffler reported that 83.3%
of pediatric patients responded to Viaskin Peanut 250 µg after three years with
a favorable safety profile and no SAE's related to treatment
An additional oral abstract, presented by FARRP, used a robust risk analysis
model to show the significant benefit associated with increasing an individual's
peanut protein threshold with immunotherapy
DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market:
DBVT) today announced that detailed results from OLFUS-VIPES, a long-term
extension study to the VIPES Phase IIb trial, were presented at the 2017
American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting in
Atlanta, Georgia, at a Late Breaking Oral Abstract Session. The Company
previously reported topline results from the OLFUS-VIPES study in October 2016.
"It is encouraging to see that with continued treatment, the effect of Viaskin
Peanut for children was sustained or increased throughout three years, while
also maintaining a favorable and easily manageable safety profile," said Dr.
Wayne Shreffler, Division of Allergy and Immunology, Department of Pediatrics,
Massachusetts General Hospital, Harvard Medical School and Investigator of the
OLFUS-VIPES Study. "Peanut allergy is one of the leading life-threatening food
allergies among children. Even with conscientious avoidance, accidental
ingestions are common and can be life-threatening."
Viaskin Peanut Highlights
Viaskin Peanut is the company's lead product candidate, based on its proprietary
EPIT platform, which aims to deliver biologically active compounds to the immune
system through the skin, and is currently being evaluated in a global, pivotal
Phase III program in peanut-allergic children four to 11 years of age. The
company also expects to initiate a Phase III trial of Viaskin Peanut in children
one to three years of age in the first half of 2017.
Late Breaking Abstract #L7
The 36-month data from the OLFUS-VIPES study, presented by Dr. Wayne Shreffler,
support the lasting response and favorable safety and tolerability profile of
Viaskin Peanut 250 µg in peanut-allergic children six to 11 years of age. The
study was also selected to be highlighted at the "Research in Food Allergy
Immunotherapy Press Event" hosted by AAAAI.
The detailed results presented today show that progressive response to treatment
was observed in children who received Viaskin Peanut 250 µg from the onset of
therapy in VIPES. After completion of three years of treatment with the 250 µg
dose, 83.3% of children in this subgroup responded to therapy compared to 53.6%
at the completion of VIPES. At the end of OLFUS, cumulative reactive doses
(CRDs) reaching 1,000 mg or more of peanut protein during the oral food
challenge were observed in 61% of children receiving Viaskin Peanut 250 µg,
which was double the number of patients reaching that CRD at the completion of
VIPES. Furthermore, 39% of children reached CRD rates of 5,040 mg or more during
the oral food challenge at the end of OLFUS. For reference, one peanut contains
approximately 250 mg of peanut protein.
Over the 36-month study period, no treatment-related serious adverse events
(SAEs) or epinephrine use was reported. In the overall population, the majority
of adverse events reported were mild and moderate application-site skin
reactions, for which severity and frequency were observed to decrease over time.
Additionally, treatment compliance, which measures adherence to treatment
dosing, remained high throughout the study at a median rate of 95.5%, and was
not impacted by the dose of Viaskin Peanut administered or the age of patients
enrolled in the study. At the end of OLFUS, the overall dropout rate due to
adverse events remained low at 2.3%.
Abstract #561
Another oral presentation featured results from a study exploring peanut
contamination cases in frequently consumed packaged foods, while assessing the
potential clinical benefit of increasing an individual's degree of
desensitization following treatment with immunotherapy. Presented by Dr. Joe
Baumert, University of Nebraska, Food Allergy Research & Resource Program
(FARRP), the study results suggested that peanut-allergic patients who can
increase their peanut sensitivity thresholds following immunotherapy are at a
much lower risk of having an allergic reaction from common packaged food items
that may contain unknown traces of peanut.
Dr. Baumert's presentation showed that increasing an individual's peanut protein
threshold, or eliciting dose, following immunotherapy would provide a
significant relative risk reduction. A greater than 99% relative risk reduction
was associated with reaching a post-therapy threshold of 300 mg if the
individual's initial eliciting dose was less than or equal to 10 mg, or reaching
a post-therapy threshold of 1,000 mg, if the individual's initial eliciting dose
was less than or equal to 300 mg.
The study was conducted using a Quantitative Risk Assessment (QRA) model
developed independently by FARRP, a leading institution focused on providing
expertise on allergenic foods and food safety. The robust QRA model used common
packaged food items such as cookies, ice cream, doughnuts/snack cakes and snack
chip mixes as references for this risk assessment. DBV provided funding for the
study and formulated the research question as related to the VIPES Phase IIb
clinical trial of Viaskin Peanut.
"This meeting at AAAAI has been filled with exciting data that highlights
Viaskin and its potential in food allergies. Our presence at AAAAI involves six
poster presentations and two oral presentations, including long-term results
from OLFUS-VIPES and important findings from FARRP, which emphasize our
commitment to developing a patient-centric, safe and effective treatment for
peanut allergy," said Dr. Pierre-Henri Benhamou, Chairman & Chief Executive
Officer of DBV Technologies. "We are very proud of these clinical and research
accomplishments, and I would like to thank all of our patients and investigators
for their support and continued efforts in moving the Viaskin Peanut development
program forward. The results we have shown over the past couple of days
highlight our dedication to bringing a treatment to peanut-allergic patients as
quickly as possible."
About the OLFUS-VIPES Study
OLFUS-VIPES (Open-Label Follow-Up Study-Viaskin Peanut's Efficacy and Safety),
or OLFUS, enrolled 171 subjects who had previously received either placebo or
one of three 12-month dose regimens administered during VIPES. During the first
year of OLFUS, patients were to receive a daily application of Viaskin Peanut
50 µg or Viaskin Peanut 100 µg or Viaskin Peanut 250 µg for 12 months. According
to a study protocol change implemented in March 2014, all patients were switched
to receive Viaskin Peanut 250 microg during OLFUS. All patients in OLFUS
maintained a peanut-free diet during the study. Baseline response levels in
OLFUS were based on the results of the last double-blind, placebo controlled
food challenge (DBPCFC) in VIPES, and adjusted by the number of patients
enrolling in OLFUS. Responders in the OLFUS trial were defined as subjects with
a peanut protein eliciting dose equal to or greater than 1,000 mg peanut protein
or with a greater than 10-fold increase of the eliciting dose compared to their
baseline eliciting dose observed in the VIPES study. Patients enrolled in OLFUS
who received placebo in VIPES were analyzed separately from subjects who
initially received Viaskin Peanut. At month 24 in OLFUS, patients who were
unresponsive to a cumulative dose above 1,440 mg were eligible to discontinue
study drug for two months while maintaining a peanut-free diet. Patients who
opted to enter into this additional period performed a DBPCFC at month-26 to
assess durability of response.
About the VIPES Study
The VIPES (Viaskin Peanut's Efficacy and Safety) trial was a double-blind,
placebo-controlled, multi-center clinical trial conducted at 22 sites in North
America and Europe. 221 peanut-allergic subjects were randomized 1:1:1:1 into
four treatment arms to evaluate three doses of Viaskin Peanut, 50 µg, 100 µg and
250 µg, compared to placebo. Each patient underwent two DBPCFCs: one at
screening and one after 12 months of treatment. The challenge was halted once
the subject exhibited an objective allergic symptom. Patients in VIPES received
a daily application of the Viaskin Peanut patch over 12 months. Each patch was
applied for 24 hours on the upper arm for adults (age 18-55) and adolescents
(age 12-17) or on the back of children (age 6-11). The primary efficacy endpoint
was the percentage of treatment responders for each active treatment group
compared to placebo. With Viaskin Peanut 250 µg, 53.6% of children were observed
to respond to treatment compared to a 19.4% response rate in the placebo group
(p=0.008). The compliance rate was more than 97% across all cohorts, the dropout
for related adverse events was less than 1%, and there were no reported serious
adverse events or epinephrine injection related to treatment.
About the PEPITES Study
The Peanut EPIT Efficacy and Safety Study (PEPITES) is a global, pivotal,
double-blinded, placebo-controlled Phase III trial designed to evaluate the
safety and efficacy of Viaskin Peanut 250 microg in children ages four to 11
years. During PEPITES, patients' response will be assessed using a double-blind,
placebo controlled food challenge (DBPCFC). Patients are randomized 2:1 to
receive either Viaskin Peanut 250 microg or placebo for 12 months. The primary
endpoint is based on a responder analysis after 12 months of treatment with
Viaskin Peanut 250 µg. For patients with a baseline peanut protein eliciting
dose (ED) equal to or less than 10 mg, a responder is defined as a patient with
a peanut protein ED equal to or greater than 300 mg of peanut protein after 12
months of treatment. For subjects with a baseline ED greater than 10 mg, a
responder is defined as a patient with a peanut protein ED equal to or greater
than 1,000 mg of peanut protein after 12 months of treatment. As a secondary
efficacy endpoint, Cumulative Reactive Dose (CRD), will also be used in PEPITES
to establish the total quantity of peanut protein that triggers patient
reactions at month 12 of active treatment versus placebo. Serological markers
will also be measured at baseline, 3, 6, and 12 months in order to characterize
the immunological changes in patients.
Following the completion of PEPITES, all patients are eligible to rollover into
PEOPLE, a long-term, open-label extension study of Viaskin Peanut 250 µg. In the
PEOPLE study, patients who were randomized to active treatment during PEPITES
will receive Viaskin Peanut 250 microg for two additional years; patients who
were previously receiving placebo during PEPITES will be treated with Viaskin
Peanut 250 microg for three years. Patients enrolling in the PEOPLE study will
remain blinded to their respective treatment group in PEPITES until the PEPITES
study results become publicly available.
About DBV Technologies
DBV Technologies is developing Viaskin®, a proprietary technology platform with
broad potential applications in immunotherapy. Viaskin is based on epicutaneous
immunotherapy, or EPIT®, DBV's method of delivering biologically active
compounds to the immune system through intact skin. With this new class of self-
administered and non-invasive product candidates, the company is dedicated to
safely transforming the care of food allergic patients, for whom there are no
approved treatments. DBV's food allergies programs include ongoing clinical
trials of Viaskin Peanut and Viaskin Milk, and preclinical development of
Viaskin Egg. DBV is also pursuing a human proof-of-concept clinical study of
Viaskin Milk for the treatment of Eosinophilic Esophagitis, and exploring
potential applications of its platform in vaccines and other immune diseases.
DBV Technologies has global headquarters in Montrouge, France and New York, NY.
Company shares are traded on segment A of Euronext Paris (Ticker: DBV, ISIN
code: FR0010417345), part of the SBF120 index, and traded on the Nasdaq Global
Select Market in the form of American Depositary Shares (each representing one-
half of one ordinary share) (Ticker: DBVT). For more information on DBV
Technologies, please visit our website: www.dbv-technologies.com
Forward Looking Statements
This press release may contain forward-looking statements and estimates,
including statements regarding the potential safety and efficacy of Viaskin
Peanut and statements reflecting management's expectations for clinical
development of our product candidates and the commercial potential of our
product candidates. These forward-looking statements and estimates are not
promises or guarantees and involve substantial risks and uncertainties. At this
stage, the products of the Company have not been authorized for sale in any
country. Among the factors that could cause actual results to differ materially
from those described or projected herein include uncertainties associated
generally with research and development, clinical trials and related regulatory
reviews and approvals, the risk that historical preclinical results may not be
predictive of future clinical trial results, and the risk that historical
clinical trial results may not be predictive of future trial results. A further
list and description of these risks, uncertainties and other risks can be found
in the Company's regulatory filings with the French Autorité des Marchés
Financiers, the Company's Securities and Exchange Commission filings and
reports, including in the Company's Annual Report on Form 20-F for the year
ended December 31, 2015 and future filings and reports by the Company. Existing
and prospective investors are cautioned not to place undue reliance on these
forward-looking statements and estimates, which speak only as of the date
hereof. Other than as required by applicable law, DBV Technologies undertakes no
obligation to update or revise the information contained in this Press Release.
DBV Technologies Contact
Susanna Mesa
Senior Vice President, Strategy
+1 212-271-0861
susanna.mesa(at)dbv-technologies.com
Media Contact
Andrea Fassacesia, Weber Shandwick
+1 212-445-8144
afassacesia(at)webershandwick.com
Media Contact Europe
Caroline Carmagnol, Alize RP, Relations Presse
+33 (0)6 64 18 99 59
caroline(at)alizerp.com
AAAAI:
http://hugin.info/156437/R/2084981/786102.pdf
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: DBV Technologies via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 05.03.2017 - 21:45 Uhr
Sprache: Deutsch
News-ID 528169
Anzahl Zeichen: 16938
contact information:
Town:
Bagneux
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 198 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DBV Technologies :Data at AAAAI 2017 Show Lasting Response and Favorable Safety Profile of Investigational Agent, Viaskin Peanut, Throughout Three Years of Treatment of Peanut Allergic Children"
steht unter der journalistisch-redaktionellen Verantwortung von
DBV Technologies (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
